Leoni Simona, Sansone Vito, Lorenzo Stefania De, Ielasi Luca, Tovoli Francesco, Renzulli Matteo, Golfieri Rita, Spinelli Daniele, Piscaglia Fabio
Internal Medicine Unit, Department of Digestive Diseases, Bologna Authority Hospital S.Orsola-Malpighi, 40136 Bologna, Italy.
Department of Medical and Surgical Sciences, University of Bologna, Via Massarenti 9, 40136 Bologna, Italy.
Cancers (Basel). 2020 Mar 26;12(4):794. doi: 10.3390/cancers12040794.
Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare primary liver cancer. It is constituted by neoplastic cells of both hepatocellular and cholangiocellular derivation. Different histology types of HCC-CC have been reported, hinting at heterogeneous carcinogenic pathways leading to the development of this cancer. Due to its rarity and complexity, mixed HCC-CC is a scantly investigated condition with unmet needs and unsatisfactory outcomes. Surgery remains the preferred treatment in resectable patients. The risk of recurrence, however, is high, especially in comparison with other primary liver cancers such as hepatocellular carcinoma. In unresectable or recurring patients, the therapeutic options are challenging due to the dual nature of the neoplastic cells. Consequently, the odds of survival of patients with HCC-CC remains poor. We analysed the literature systematically about the treatment of mixed HCC-CC, reviewing the main therapeutic options and their outcomes and analysing the most interesting developments in this topic with a focus on new potential therapeutic avenues.
肝细胞胆管癌（HCC-CC）是一种罕见的原发性肝癌。它由肝细胞和胆管细胞来源的肿瘤细胞组成。已报道了不同组织学类型的HCC-CC，这暗示了导致该癌症发生的致癌途径具有异质性。由于其罕见性和复杂性，混合性HCC-CC是一种研究较少的疾病，存在未满足的需求且治疗效果不理想。手术仍然是可切除患者的首选治疗方法。然而，复发风险很高，尤其是与其他原发性肝癌如肝细胞癌相比。在不可切除或复发的患者中，由于肿瘤细胞的双重性质，治疗选择具有挑战性。因此，HCC-CC患者的生存几率仍然很低。我们系统地分析了关于混合性HCC-CC治疗的文献，回顾了主要的治疗选择及其结果，并分析了该主题中最有趣的进展，重点关注新的潜在治疗途径。
